Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis

被引:6
|
作者
Qin, Jiading [1 ,2 ]
Ke, Bo [2 ,3 ]
Liu, Tingting [2 ]
Kong, Chunfang [1 ,2 ]
Li, Anna [2 ]
Fu, Huan [2 ]
Jin, Chenghao [1 ,2 ,3 ]
机构
[1] Nanchang Univ, Med Coll, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangxi Prov Peoples Hosp, Dept Hematol, Nanchang 330006, Jiangxi, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Jiangsu, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
基金
中国国家自然科学基金;
关键词
clinical prognosis; long noncoding RNA; meta-analysis; multiple myeloma; predictive biomarker; CANCER; RESISTANCE; KNOCKDOWN; TUG1; PVT1; BIAS; H19;
D O I
10.1002/cam4.5135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Numerous studies have manifested long noncoding RNAs (lncRNAs) as biomarkers to determine the prognosis of multiple myeloma (MM) patients. Nevertheless, the prognostic role of lncRNAs in MM is still ambiguous. Herein, we performed a meta-analysis to evaluate the predictive value of aberrantly expressed lncRNAs in MM. Methods A systemic literature search was performed in PubMed, EMBASE, Cochrane, and Web of Science databases until October 9, 2021, and the protocol was registered in the PROSPERO database (CRD42021284364). Our study extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), or event-free survival (EFS). Begg's and Egger's tests were employed to correct publication bias. Result Twenty-six individual studies containing 3501 MM patients were enrolled in this study. The results showed that aberrant expression of lncRNAs was associated with poor OS and PFS of MM patients. The pooled HRs for univariate OS and PFS were 1.48 (95% CI = 1.17-1.88, p < 0.001) and 1.30 (95% CI = 1.18-1.43, p < 0.001), respectively, whereas the pooled HRs for multivariate OS and PFS were 1.50 (95% CI = 1.16-1.95, p < 0.001) and 1.59 (95% CI = 1.22-2.07, p < 0.001), respectively. Subgroup analysis suggested that MALAT1, TCF7, NEAT1, and PVT1 upregulation were associated with poor OS (p < 0.05), PVT1, and TCF7 upregulation were implicated with worse PFS (p < 0.05), while only TCF7 overexpression was correlated with reduced EFS (p < 0.05). Moreover, the contour-enhanced funnel plot demonstrated the reliability of our current conclusion, which was not affected by publication bias. Conclusion Aberrantly expressed particular lncRNAs are critical prognostic indicators in long-term survival as well as promising biomarkers in progression-free status. However, different cutoff values and dissimilar methods to assess lncRNA expression among studies may lead to heterogeneity.
引用
收藏
页码:2199 / 2218
页数:20
相关论文
共 50 条
  • [31] Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis
    Chakraborty, Rajshekhar
    Malik, Saad Ullah
    Marneni, Naimisha
    Garcia, Alex V. Mejia
    Anwer, Faiz
    Khorana, Alok A.
    Majhail, Navneet S.
    BLOOD, 2018, 132
  • [32] The Potential Diagnostic Value of Exosomal Long Noncoding RNAs in Solid Tumors: A Meta-Analysis and Systematic Review
    Wu, Zilong
    Xu, Zihao
    Yu, Boyao
    Zhang, Jingtao
    Yu, Bentong
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [33] Prognostic Role of Long Noncoding RNAs in Oral Squamous Cell Carcinoma: A Meta-Analysis
    Wang, Yu
    Wang, Peng
    Liu, Xin
    Gao, Ziran
    Cao, Xianbao
    Zhao, Xilong
    DISEASE MARKERS, 2021, 2021
  • [34] Efficacy of Maintenance Therapies By Prognostic Subgroups in Post-Transplant Newly Diagnosed Multiple Myeloma Patients: A Systematic Review and Network Meta-Analysis
    Asghar, Noureen
    Naqvi, Syed Arsalan
    Asghar, Kanwal
    Thirumalareddy, Joseph
    Asghar, Noureen
    Husnain, Muhammad
    Chakraborty, Rajshekhar
    Devrieze, Bradley
    Mathews, Abraham
    Bin Riaz, Irbaz
    Aljama, Mohammed
    BLOOD, 2023, 142
  • [35] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
    Wang, Yin-Che
    Lin, Cheng-Hsien
    Su, Yu-Chen
    Teng, Chieh-Lin Jerry
    HEMATOLOGY, 2025, 30 (01)
  • [36] Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
    Sun, Chun-yan
    Li, Jun-ying
    Chu, Zhang-bo
    Zhang, Lu
    Chen, Lei
    Hu, Yu
    BIOSCIENCE REPORTS, 2017, 37
  • [37] Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis
    Channar, Aneeta
    Naqvi, Syed Arsalan Ahmed
    Khan, Muhammad Ali
    Bibi, Arifa
    Saxena, Akshat
    Tripathi, Nikita
    Iftikhar, Ahmad
    Raina, Ammad
    Khakwani, Kaneez Zahra Rubab
    Bin Riaz, Irbaz
    Husnain, Muhammad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Ixazomib Based Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials
    Javaid, Anum
    Razzaq, Faryal
    Ali, Muhammad Ashar
    Abu Zar, Muhammad
    Sohail, Atif
    Iftikhar, Ahmad
    Usman, Rana
    Anwar, Muhammad Yasir
    Hassan, Hamza
    Anwer, Faiz
    BLOOD, 2020, 136
  • [39] A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents
    Su, Baohua
    Zhu, Xu
    Jiang, Yina
    Wang, Lida
    Zhao, Ningning
    Ran, Xuehong
    Zhen, Xiaobin
    Guo, Hui
    LEUKEMIA & LYMPHOMA, 2019, 60 (06) : 1381 - 1388
  • [40] Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: A systematic review and meta-analysis
    Balitsky, Amaris K.
    Karkar, Aram
    McCurdy, Arleigh
    Rochwerg, Bram
    Mian, Hira S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 626 - 634